OmniAb, Inc.
Diego Espinosa has solid experience in the field of scientific research and analysis. Diego currently holds the position of Sr. Research Scientist at OmniAb, Inc. since November 2022. Prior to this, they worked as a Sr. Research Scientist at Ligand Pharmaceuticals from September 2022 to November 2022. From June 2020 to September 2022, Diego was a Scientist at Metagenomi. Diego also has experience at Boehringer Ingelheim, where they worked as a Scientist III from May 2019 to June 2020, specializing in HPLC-based methods and antibody purification. Before that, Diego served as a Postdoctoral Scholar at the University of California, Berkeley from October 2015 to March 2019, focusing on research projects related to dengue and Zika viruses. Additionally, they worked as a Scientific Consultant at PaxVax, Inc. from March 2018 to December 2018. Diego Espinosa has consistently demonstrated expertise and dedication in their scientific career.
Diego Espinosa has a strong education background in the field of science. Diego obtained a Bachelor of Science degree in Biology, General from the Universidad Peruana Cayetano Heredia, completing their studies from 2002 to 2006. Building upon this foundation, they pursued further education at the Johns Hopkins Bloomberg School of Public Health, where they earned a Doctor of Philosophy (Ph.D.) in Molecular Microbiology and Immunology. This extensive academic journey spanned from 2009 to 2015.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.